NCT05546255 is a Phase 2 clinical trial of Eribulin Mesylate in Triple Negative Breast Cancer, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT05546255?

NCT05546255 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05546255?

Interventions in NCT05546255: Eribulin Mesylate, Lobaplatin.

What condition does NCT05546255 study?

NCT05546255 studies Triple Negative Breast Cancer.

Is NCT05546255 still recruiting?

NCT05546255 is currently status unknown. Last updated 19 September 2022.

Last reviewed 2022-09-19 · How we verify

NCT05546255

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Status unknown Phase 2 Last updated 19 September 2022

What this trial tests

Phase 2 trial testing Eribulin Mesylate in Triple Negative Breast Cancer in 40 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 December 2022

31 December 2023

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 June 2020
Primary completion	1 December 2022
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Eribulin Mesylate — full drug profile →
Lobaplatin — full drug profile →

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 75, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective phase II study conducted at the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of eribulin combined with lobaplatin in the treatment of recurrent or metastatic triple-negative breast cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Eribulin Mesylate

Trials testing the same drug.

NCT06590558 — Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Er · Phase 1 · withdrawn
NCT05041101 — Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer · Phase 1, PHASE2 · terminated
NCT04579224 — Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel · Phase 3 · active not recruiting
NCT04345913 — Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · Phase 1, PHASE2 · active not recruiting
NCT05206656 — Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer · Phase 2 · completed

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05546255 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 19 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05546255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing